FY2024 Earnings Forecast for Femasys Issued By HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of Femasys in a research report issued to clients and investors on Tuesday, November 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.84) per share for the year, down from their previous forecast of ($0.78). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.22) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.04) EPS.

Separately, Chardan Capital dropped their target price on Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday.

Femasys Trading Down 2.8 %

NASDAQ:FEMY opened at $0.95 on Friday. The business’s 50-day moving average is $1.16 and its two-hundred day moving average is $1.15. The firm has a market capitalization of $21.82 million, a PE ratio of -1.18 and a beta of -2.83. Femasys has a 12 month low of $0.73 and a 12 month high of $2.40. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 5.93.

Femasys (NASDAQ:FEMY) last issued its earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The business had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.40 million.

Hedge Funds Weigh In On Femasys

Institutional investors have recently added to or reduced their stakes in the company. Aljian Capital Management LLC purchased a new stake in shares of Femasys during the third quarter worth about $27,000. XTX Topco Ltd grew its stake in Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares in the last quarter. Finally, CM Management LLC increased its holdings in Femasys by 6.3% during the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.